January 2020 archive

Ovarian Cancer Moon Shot works to broaden immunotherapy impact

January 30, 2020

Immunotherapies have brought the potential for long-term remission and even cures to patients with many cancer types, but the benefits have not yet extended to all patients or all cancer types. Ovarian cancer is one such example.

MD Anderson’s Ovarian Cancer Moon Shot® seeks to change this by exploring the use of immunotherapy to bring lasting results to more patients.

Amir Jazaeri, M.D., professor of Gynecologic Oncology...

Amir Jazaeri, M.D., says immunotherapy clinical trials target ovarian cancer patients whose disease has become resistant to chemotherapy.

Melanoma expert Hussein Tawbi, M.D., Ph.D.

Hussein Tawbi named to President’s Council on Science and Technology

BY Scott Merville

January 28, 2020

President Donald Trump today announced his intent to appoint Hussein Tawbi, M.D., Ph.D., associate professor and deputy chairman of Melanoma...

Sattva Neelapu, M.D., Ph.D., notes that 80% of relapsed, refractory large B-cell lymphoma patients respond to CAR T cell therapy, but only about 40% enjoy long-term remission.

Making CAR T cell therapy more effective for B-cell lymphoma treatment

BY Clayton Boldt, Ph.D.

January 24, 2020

Chimeric antigen receptor (CAR) T cells were approved by the Food and Drug Administration (FDA) to treat relapsed and refractory large B-cell...

MD Anderson accelerates cellular therapy programs by buying state-of-art manufacturing facility

BY Clayton R. Boldt, Ph.D.

January 21, 2020

Cellular therapies have emerged as an effective new therapy for patients with certain types of cancer, and MD Anderson has played an important role in advancing these novel treatments to the clinic. With recent agreements, MD Anderson has expanded its manufacturing and research capacity for cell therapies to bring new treatment options to more patients.

This month, MD Anderson finalized an asset purchase agreement with Bellicum...